TFF3 and gastric cancer: TFF3 levels were significantly different between GC stage I (9.913 ± 0.841 ng/mL) and H (6.195 ± 0.702 ng/mL) (p = 0.001) and CDH17 levels between GC stages II (0.578 ± 0.091 ng/mL) and III (0.549 ± 0.088 ng/mL) and H samples (0.329 ± 0.060 ng/mL) (p = 0.023 and 0.037, respectively).